文献速递生殖医学

基于卵巢储备检测的个体化FSH剂量用于开始IVF/ICSI的女性:多中心试验与成本效果分析

Individualized FSH dosing based on ovarian reserve testing in women starting IVF/ICSI: a multicentre trial and cost-effectiveness analysis.
PubMed 文献 · Hum Reprod · 2017-01-01

这项多中心前瞻性队列研究嵌套两个随机对照试验,纳入1515名计划行IVF/ICSI的女性,比较基于窦卵泡计数(AFC)的个体化FSH剂量与标准FSH剂量的活产率和成本效果。个体化策略组活产率为56.3%(420/747),标准策略组为58.2%(447/769),风险差-0.019(95% CI,-0.06至0.02),P=0.39,差异无统计学意义;个体化策略每名女性成本增加275欧元(95% CI,40至499)。作者结论认为,对于整体IVF/ICSI人群,不应采用个体化FSH剂量,因该策略不改善活产率且增加成本。

要点

  • 个体化FSH剂量组活产率56.3%(420/747),标准剂量组58.2%(447/769),风险差-0.019(95% CI,-0.06至0.02),P=0.39。
  • 个体化策略每名女性成本增加275欧元(95% CI,40至499),但轻度及中度卵巢过度刺激综合征(OHSS)发生减少,相关管理成本每名女性节省35欧元。
  • 作者建议,月经周期规律的IVF/ICSI女性采用标准FSH起始剂量150 IU/天;预测高反应者的个体化剂量安全性管理有待进一步研究。

核心结论

  • 对于开始IVF/ICSI的女性,基于AFC的个体化FSH剂量与标准FSH剂量相比,不改善活产率且增加成本。
  • 作者建议月经周期规律的IVF/ICSI女性采用标准FSH起始剂量150 IU/天。
  • 作者认为,预测高反应者采用个体化剂量进行安全性管理仍有待进一步研究。

研究设计与样本

  • 2011年5月至2014年5月开展的多中心前瞻性队列研究,嵌套两个随机对照试验(RCT)。
  • 根据AFC将女性分入RCT1(AFC<11)、RCT2(AFC>15)或队列(AFC 11-15)。
  • RCT1中个体化组FSH剂量为450/225 IU,RCT2中个体化组为100 IU,标准组均为150 IU;队列中所有女性接受标准剂量150 IU。
  • 共纳入1515名女性,其中483名(31.9%)进入队列,511名(33.7%)进入RCT1,521名(34.4%)进入RCT2。
  • 主要结局为随机化后18个月内实现的持续妊娠并活产(妊娠24周后至少分娩一个活胎)。

主要发现

  • 个体化策略组活产420/747(56.3%),标准策略组活产447/769(58.2%),风险差-0.019(95% CI,-0.06至0.02),P=0.39;因半整数四舍五入,总数为1516名女性。
  • 个体化策略每名女性成本增加275欧元(95% CI,40至499)。
  • 个体化剂量减少了轻度和中度OHSS的发生,随后减少了这些OHSS类别的管理成本,每名女性节省35欧元。
  • 基于AMH作为剂量个体化工具的分析显示了可比的结果。

关键数值与推荐

  • RCT1(AFC<11)个体化FSH剂量为450/225 IU,RCT2(AFC>15)个体化FSH剂量为100 IU。
  • 标准FSH剂量为150 IU;队列(AFC 11-15)女性全部接受标准剂量150 IU。
  • RCT1中仅标准组允许根据预设标准在后续周期调整剂量;RCT2中两组均允许在后续周期调整剂量。

临床怎么用

  • 作者建议,月经周期规律的IVF/ICSI女性采用标准FSH起始剂量150 IU/天。
  • 作者认为,对于整体IVF/ICSI人群,不应追求个体化FSH剂量,因其不改善活产率且增加成本。
  • 作者指出,预测高反应者通过个体化剂量进行安全性管理仍有待进一步研究。

局限性

  • 尽管有培训计划,AFC可能存在观察者间变异。
  • 尽管提供了严格的取消标准,但不能排除个体化剂量组的选择性取消(特别是针对反应不良者),因为观察者对FSH剂量未设盲,且后续周期允许小幅剂量调整。
  • 然而,由于两策略间第一周期活产率和累积活产率均无差异,开放设计可能并未掩盖个体化组的潜在获益。
  • 尽管越来越多共识认为预测高反应女性应使用GnRH拮抗剂联合治疗,但本研究中近80%的女性使用了GnRH激动剂。
  • 因此,在这些女性中,AFC和用于事后AMH分析的血样采集是在垂体抑制期间进行的;由于GnRH激动剂使用期间AFC与卵巢反应的相关性未受损,这可能未影响反应分类。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Is there a difference in live birth rate and/or cost-effectiveness between antral follicle count (AFC)-based individualized FSH dosing or standard FSH dosing in women starting IVF or ICSI treatment? SUMMARY ANSWER: In women initiating IVF/ICSI, AFC-based individualized FSH dosing does not improve live birth rates or reduce costs as compared to a standard FSH dose. WHAT IS KNOWN ALREADY: In IVF or ICSI, ovarian reserve testing is often used to adjust the FSH dose in order to normalize ovarian response and optimize live birth rates. However, no robust evidence for the (cost-)effectiveness of this practice exists. STUDY DESIGN, SIZE, DURATION: Between May 2011 and May 2014 we performed a multicentre prospective cohort study with two embedded RCTs in women scheduled for IVF/ICSI. Based on the AFC, women entered into one of the two RCTs (RCT1: AFC < 11; RCT2: AFC > 15) or the cohort (AFC 11-15). The primary outcome was ongoing pregnancy achieved within 18 months after randomization resulting in a live birth (delivery of at least one live foetus after 24 weeks of gestation). Data from the cohort with weight 0.5 were combined with both RCTs in order to conduct a strategy analysis. Potential half-integer numbers were rounded up. Differences in costs and effects between the two treatment strategies were compared by bootstrapping. PARTICIPANTS/MATERIALS, SETTING, METHODS: In both RCTs women were randomized to an individualized (RCT1:450/225 IU, RCT2:100 IU) or standard FSH dose (150 IU). Women in the cohort all received the standard dose (150 IU). Anti-Müllerian hormone (AMH) was measured to assess AMH post-hoc as a biomarker to individualize treatment. For RCT1 dose adjustment was allowed in subsequent cycles based on pre-specified criteria in the standard group only. For RCT2 dose adjustment was allowed in subsequent cycles in both groups. Both effectiveness and cost-effectiveness of the strategies were evaluated from an intention-to-treat perspective. MAIN RESULTS AND THE ROLE OF CHANCE: We included 1515 women, of whom 483 (31.9%) entered the cohort, 511 (33.7%) RCT1 and 521 (34.4%) RCT2. Live births occurred in 420/747 (56.3%) women in the individualized strategy and 447/769 (58.2%) women in the standard strategy (risk difference -0.019 (95% CI, -0.06 to 0.02), P = 0.39; a total of 1516 women due to rounding up the half integer numbers). The individualized strategy was more expensive (delta costs/woman = €275 (95% CI, 40 to 499)). Individualized dosing reduced the occurrence of mild and moderate ovarian hyperstimulation syndrome (OHSS) and subsequently the costs for management of these OHSS categories (costs saved/woman were €35). The analysis based on AMH as a tool for dose individualization suggested comparable results. LIMITATIONS, REASONS FOR CAUTION: Despite a training programme, the AFC might have suffered from inter-observer variation. In addition, although strict cancel criteria were provided, selective cancelling in the individualized dose group (for poor response in particular) cannot be excluded as observers were not blinded for the FSH dose and small dose adjustments were allowed in subsequent cycles. However, as both first cycle live birth rates and cumulative live birth rates show no difference between strategies, the open design probably did not mask a potential benefit for the individualized group. Despite increasing consensus on using GnRH antagonist co-treatment in women predicted for a hyper response in particular, GnRH agonists were used in almost 80% of the women in this study. Hence, in those women, the AFC and bloodsampling for the post-hoc AMH analysis were performed during pituitary suppression. As the correlation between AFC and ovarian response is not compromised during GnRH agonist use, this will probably not have influenced classification of response. WIDER IMPLICATIONS OF THE FINDINGS: Individualized FSH dosing for the IVF/ICSI population as a whole should not be pursued as it does not improve live birth rates and it increases costs. Women scheduled for IVF/ICSI with a regular menstrual cycle are therefore recommended a standard FSH starting dose of 150 IU per day. Still, safety management by individualized dosing in predicted hyper responders is open for further research. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by The Netherlands Organisation for Health Research and Development (ZonMW number 171102020). AMH measurements were performed free of charge by Roche Diagnostics. TCT, HLT and SCO received an unrestricted personal grant from Merck BV. AH declares that the department of Obstetrics and Gynecology, University Medical Centre Groningen receives an unrestricted research grant from Ferring pharmaceutics BV, The Netherlands. CBL receives grants from Merck, Ferring and Guerbet. BWJM is supported by a NHMRC Practitioner Fellowship (GNT1082548) and reports consultancy for OvsEva, Merck and Guerbet. FJMB receives monetary compensation as a member of the external advisory board for Ferring pharmaceutics BV (the Netherlands) and Merck Serono (the Netherlands) for consultancy work for Gedeon Richter (Belgium) and Roche Diagnostics on automated AMH assay development (Switzerland) and for a research cooperation with Ansh Labs (USA). All other autors have nothing to declare. TRIAL REGISTRATION NUMBER: Registered at the ICMJE-recognized Dutch Trial Registry (www.trialregister.nl). Registration number: NTR2657.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. van Tilborg TC, Oudshoorn SC, Eijkemans MJC, et al. Individualized FSH dosing based on ovarian reserve testing in women starting IVF/ICSI: a multicentre trial and cost-effectiveness analysis. Hum Reprod. 2017. PMID: 29121350. doi:10.1093/humrep/dex321

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。